

## Programme Themes and Features

The three main themes of the symposium will be:

- Innovative synthesis facilitating candidate discovery
- Novel bioisosteres and methodology applicable to drug discovery
- Overcoming challenges of scale-up and process scale chemistry

## Registration, Students and Bursaries

Registration is open and fees are:

- £85 RSC member
- £105 Non-member
- £55 RSC student\* member
- £75 Student\* non-member

\* Student means undergraduate or post-graduate, not post-doc

Some RSC BMCS student bursaries are available to support registration, travel and accommodation costs for PhD and post-doctoral applicants studying at European academic institutions. Please download an application form from the website and note the closing date of 6th February.

## Exhibition Opportunities

There will be a small relevant trade exhibition, and those companies wishing to exhibit should book early as spaces will be limited. The fee is £485 for the exhibitor package (see website for details) including one full delegate. Delegate pack inserts may also be booked.

## Venue and Travel

Address: Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK  
Travel: Windlesham is a 30-minute taxi-ride from Heathrow airport, a 50-minute train journey from London (to Ascot), and is easily accessible by car (M3, junction 3).

## Sponsorship

We are grateful to Lilly for their generous support of this symposium, and additional sponsors are sought to support the low registration fees offered to student attendees.

## Secretariat Contact

Maggi Churchouse, +44 (0)1359 221004  
maggi@maggichurchousevents.co.uk

## Websites

<https://www.maggichurchousevents.co.uk/bmcs>  
also [www.rsc.org/bmcs](http://www.rsc.org/bmcs)

## Organising Committee

Nadia Ahmad  
Duncan Hay (chairman), Vertex  
Martin Swarbrick, Cancer Research UK  
Andrew Williams, Lilly

## Call for Posters

Applications are invited for poster presentation. Posters will be displayed throughout the day and applicants are asked if they wish to provide a two-minute flash oral presentation when submitting their abstracts. The closing date for submission is 30th January.

# Second Announcement and Call for Posters

*Celebrating Synthesis:  
the Heart of Drug Discovery  
and Development*



*Synthesis in Drug Discovery & Development*  
*Friday, 27<sup>th</sup> March 2020*

*Lilly Research Centre, Windlesham, Surrey, UK*



# Synthesis in Drug Discovery and Development

## Synopsis

Synthesis is at the heart of drug discovery and development. The industry has increasingly demanded higher quality clinical candidates and has sought to exploit less druggable biological targets. Densely functionalised small molecules with a high degree of synthetic complexity are often the result of these demands. Successful programmes therefore require the application of innovative synthesis in all stages of discovery and development. The medicinal chemist's toolbox is also enhanced by the introduction of novel bioisosteres, often made available only through the application of new synthetic methods. This symposium aims to celebrate the crucial role of synthesis in the success of drug discovery and development.

## Who should attend

Chemists from industry and academia, including synthetic, medicinal and process chemists.

## Programme (provisional)

- 09.00 Registration, refreshments and exhibition  
09.55 Opening remarks
- Session 1: Medicinal Chemistry  
Session chair:
- 10.00 *Innovative synthetic methods and their application to the discovery of ATAD2 inhibitors*  
Carine Guérot, AstraZeneca
- 10.30 *Development and application of facile and flexible 2+2+2 cyclo-trimerisation methodology and its impact on two lead identification programmes*  
Simon Peace, GlaxoSmithKline
- 11.00 *Modern organic synthesis in the discovery of chemical probes for new targets*  
Paul Brennan, Structural Genomics Consortium
- 11.30 Flash poster presentations
- 12.00 Lunch, exhibition and posters

Twitter Hashtag

#SDDD20

# Synthesis in Drug Discovery and Development

## Programme (continued)

- Session 2: Isosteres  
Session chair:
- 13.30 *Discovery, application and conformational bias of aryl 3-oxabicyclo[4.1.0]heptanes, non-nitrogen containing bioisosteres of N-aryl morpholines*  
Heather Hobbs, GlaxoSmithKline
- 14.00 *New synthetic chemistry for the exploration of 3-D pharmaceutical space*  
Peter O'Brien, University of York
- 14.30 *Synthesis of new chemical motifs as design options for drug discovery*  
James Bull, Imperial College London
- 15.00 *Sp<sup>3</sup>-rich cyclic hydrazine frameworks for drug discovery*  
Mike Shipman, University of Warwick
- 15.30 Refreshments, exhibition and posters
- Session 3: Scale-up  
Session chair:
- 16.00 *Bioisosteric replacements and scale-up challenges in drug discovery*  
Thomas Fessard, SpiroChem
- 16.30 *Glucose responsive insulin - synthesis enabling discovery and development*  
Paul Bulger, MSD
- 17.00 *A 3-way BET to scale up a trans-disubstituted dihydrobenzofuran active bromodomain inhibitor*  
Catherine Alder, GlaxoSmithKline
- 17.30 Close